The flu is a health risk for Canadians. It causes up to 15,000 hospitalizations every year and is one of the top 10 causes of death. Getting a flu vaccine is the best way to prevent the flu and any severe complications. Unfortunately, many Canadians do not get the flu vaccine. A recent survey found that less than a quarter of healthy adults got the flu vaccine.
In Canada, current standard access to influenza vaccination is at physician offices, public health clinics, or pharmacy. Therefore, this study is testing a novel access route to influenza vaccine. This study will answer the question: "Will self-administration at home of FLUMIST through a pharmacy pick up model increase uptake of influenza vaccination compared to usual care?" FLUMIST is a needle-free vaccine given as a nasal spray.
Households will be randomly chosen to either be offered the FLUMIST vaccine that can be given at home or to make their own choice for the flu season, which may or may not include vaccination.

Start Date15 Oct 2026

Sponsor / Collaborator

McMaster University

NCT07726862

/ Not yet recruitingPhase 4IIT

Characterizing Local Mucosal Responses to Live Attenuated Influenza Vaccine in Healthy Adults

This study is looking at how the immune system in the nose responds after receiving the FluMist nasal flu vaccine in healthy adults. FluMist is an FDA-approved influenza vaccine that is given as a nasal spray.
Healthy volunteers aged 18 to 65 who do not have chronic medical conditions, do not smoke, and have not recently received a flu vaccine will be enrolled. Participants will have three study visits over approximately one week. At the first visit, participants will be screened, give informed consent, and receive the FluMist vaccine. Nasal swabs and a gentle saline nasal wash will be collected before vaccination and again at two and four days after vaccination.
The samples collected will be used to study changes in immune cells, proteins, and viral activity in the nose using laboratory techniques such as gene expression and protein analysis. This information may help researchers better understand how flu vaccines work at the site where infection begins and may support the development of improved vaccines in the future.
There is no direct medical benefit expected for participants. Participation is voluntary, and all study procedures will be performed by trained clinical staff.

Start Date01 Oct 2026

Sponsor / Collaborator

The University of Alabama at Birmingham

NCT07240922

/ Active, not recruitingPhase 4IIT

The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study - a Randomized Controlled Trial

This study will provide novel insight into the effects of repeat influenza vaccination with Flublok and FluMist on the strength and breadth of immune responses to influenza, the mechanisms underlying heterogeneity in vaccine response and vaccine failure, and biological factors that could explain variation in influenza vaccine effectiveness.

Start Date01 Oct 2025

Sponsor / Collaborator

The University of Hong Kong

100 Clinical Results associated with Influenza virus vaccine live intranasal (quadrivalent)(MedImmune LLC)

100 Translational Medicine associated with Influenza virus vaccine live intranasal (quadrivalent)(MedImmune LLC)

100 Patents (Medical) associated with Influenza virus vaccine live intranasal (quadrivalent)(MedImmune LLC)

107

Literatures (Medical) associated with Influenza virus vaccine live intranasal (quadrivalent)(MedImmune LLC)

29 Apr 2026·Science Translational Medicine

Local B cell immunity and durable memory after live-attenuated influenza intranasal vaccination of humans.

Article

Author: Lopez, Paul G ; Stacey, Hannah D ; Crotty, Shane ; Krammer, Florian ; Bhavsar, Disha ; Garin-Ortega, Lucas ; Faraji, Farhoud ; Ramirez, Sydney I ; Ramezani-Rad, Parham ; Levi, Gina

Seasonal influenza vaccines are most frequently delivered as intramuscular inactivated vaccines, which elicit systemic responses against the immunodominant hemagglutinin (HA) head domain. An intranasally administered, live-attenuated influenza vaccine designed to stimulate mucosal immunity, FluMist, is the sole intranasal vaccine approved in the United States. However, FluMist has lower systemic immunogenicity and efficacy in adults compared with intramuscular formulations. In this study, human mucosal and systemic immunity were examined after seasonal intramuscular or intranasal vaccination. Nasopharyngeal swabs of adenoid tissue were used to longitudinally sample the upper airway. FluMist induced substantial increases in upper respiratory tract IgG⁺ and IgA⁺ HA-specific memory B cells, which displayed an activated CD27⁺CD21^- phenotype. H1, H3, and influenza B virus HA-specific memory B cells were all detected in the upper airway after intranasal immunization, remained elevated at 6 months postvaccination, and were associated with the presence of circulating T follicular helper (cT_FH) cells. Recently activated upper airway memory B cells were not readily detected in intramuscular vaccinees, despite the elevation of systemic antibodies and circulating HA-specific memory B cells. Thus, despite minimal immune responses detected in circulation, adults vaccinated with the live-attenuated influenza vaccine generate substantial local antigen-specific memory B cell responses. These findings have implications for improving influenza vaccines and for mucosal vaccination against other respiratory pathogens.

01 Aug 2025·JOURNAL OF CONTROLLED RELEASE

Broadly active intranasal influenza vaccine with a nanocomplex particulate adjuvant targeting mast cells and toll-like receptor 9

Article

Author: Williamson, Grace L ; Staats, Herman F ; Lukesh, Nicole R ; Petrovsky, Nikolai ; Hendy, Dylan A ; Ashcraft, Kathleen A ; Abraham, Mathew A ; Ross, Ted M ; Bachelder, Eric M ; Murphy, Connor T ; Heise, Mark T ; Landon, Chelsea D ; Pena, Erik S ; Carlock, Michael ; Abraham, Soman N ; Ontiveros-Padilla, Luis ; Ainslie, Kristy M

Flumist is the only FDA-approved intranasal influenza vaccine. Although it has recently been approved for at-home use, it has significant limitations. These include reduced effectiveness in generating a protective immune response in patients with extensive influenza exposure, safety concerns due to its live attenuated virus formulation, and reduced efficacy due to viral drift/shift. To address this limitation, we have developed a nanocomplex comprised of a mast cell (MC) agonist and toll-like receptor 9 (TLR9) ligand to adjuvant a broadly acting influenza antigen. The newly reported MC agonist was identified by screening mastoparan-7 analogs for MC degranulation activity, which led to a more active peptide analog, MP12W. Positively charged MP12W spontaneously forms nanoparticulate complexes (NPs) with CpG 1826 that were then used to intranasally vaccinate mice with a computationally optimized broadly reactive antigen (COBRA) hemagglutinin (HA) protein. The NPs were further optimized by substituting CpG 1826 with CpG 55.2, a TLR-9 agonist identified by machine learning to be more active in humans. MP12W-CpG 1826 NPs showed an increased pro-inflammatory response and decreased cytotoxicity in vitro compared to M7 complexes, translating into a safer profile in a model of increased hypersensitivity, collaborative cross mice 027 (CC027). Intranasal vaccination with this complex and broadly reactive HA resulted in higher mucosal antibody concentration and increased cytokine production with antigen recall. These responses were enhanced with MP12W-CpG 55.2 NP vaccination. MP12W-CpG NPs provided similar protection in an influenza challenge model. This study demonstrates the potential of this novel intranasal nanocomplex for vaccination.

01 Feb 2025·JOURNAL OF INFECTION AND CHEMOTHERAPY

The efficacy and safety of a quadrivalent live attenuated influenza nasal vaccine in Japanese children: A phase 3, randomized, placebo-controlled study

Article

Author: Oe, Keiji ; Hayashi, Takuya ; Nakayama, Tetsuo ; Makino, Kentaro

BACKGROUND:

Vaccination is the primary method of preventing influenza infection and complications in young children. We evaluated the efficacy and safety of a single dose of MEDI3250 (intranasal, quadrivalent, live attenuated influenza vaccine) in healthy Japanese children during the 2016/17 influenza season.

METHODS:

In this multicenter, randomized, double-blind, phase 3 study (jRCT2080223345), participants aged 2-18 years received MEDI3250 or placebo (2:1), stratified by age (2-6 years, 7-18 years). The primary and secondary endpoints were the incidence of confirmed symptomatic onset of influenza caused by a circulating wild-type strain or by a vaccine-matched strain, respectively. Safety outcomes included the incidence of adverse events (AEs) and vaccine-related AEs.

RESULTS:

Overall, 910 participants received MEDI3250 (n = 608) or placebo (n = 302). For the primary endpoint (regardless of the influenza subtype), the incidence of influenza onset was 25.5 % (MEDI3250) and 35.9 % (placebo); relative risk reduction, 28.8 % (95 % confidence interval, 12.5 %, 42.0 %). For the secondary endpoint (vaccine-matched strain), the incidence was 10.9 % (MEDI3250) and 17.2 % (placebo); relative risk reduction, 36.6 % (95 % confidence interval, 6.5 %, 56.8 %). Solicited AEs occurred in 67.6 % (MEDI3250) and 63.6 % (placebo). Most events were mild; nasal discharge was most common (59.2 % [MEDI3250] and 52.6 % [placebo]). Unsolicited AEs occurred in 36.0 % (MEDI3250) and 33.1 % (placebo). The most common unsolicited vaccine-related AE was diarrhea (2.3 %, both groups).

CONCLUSIONS:

MEDI3250 had a greater preventive effect against influenza onset in Japanese children than placebo; no new safety signals were observed relative to previous clinical and post-marketing studies of MEDI3250.

News (Medical) associated with Influenza virus vaccine live intranasal (quadrivalent)(MedImmune LLC)

05 Jan 2026

·www.einpresswire.com

Zest Clinic Introduces Needle-Free Intranasal Influenza Vaccine FluMist in Singapore

Zest Clinic announced the introduction of FluMist, a needle-free intranasal influenza vaccine, as part of its preventive health services. Getting vaccinated is the simplest way to protect yourself and your loved ones. With needle-free options like FluMist, staying protected has never been easier.” — Dr Sankeerth Reddy SINGAPORE, SINGAPORE, January 6, 2026 / EINPresswire.com / -- Zest Clinic, a medical aesthetics and wellness clinic in Marine Parade, announced the introduction of FluMist, a needle-free intranasal influenza vaccine, as part of its preventive health services. Known to many patients as a longevity clinic and Botox clinic , Zest Clinic is broadening its focus on health and longevity by adding more vaccination options alongside its wellness services. The new offering sits within the clinic’s existing wellness portfolio. Patients who attend for skin, hair or anti-ageing concerns – including treatments such as collagen booster injection – will now be able to discuss influenza prevention during the same visit, where appropriate. By bringing aesthetic medicine and preventive healthcare together, the clinic aims to make conversations about long-term health more fun and engaging. Zest Clinic’s doctors also provide injectable treatments for facial volume and contouring, such as sculptra injections and are accustomed to counselling patients about risk, benefit and suitability. The same consultation-led approach will be used when discussing whether FluMist or a traditional injectable flu vaccine is the better option for an individual patient. For those who avoid the annual vaccination due to fear of needles or pain concerns, this is a must have. With the influenza season at its peak, this offers a painless approach to protect yourself and your loved ones from Influenza viruses. FluMist is an intranasal, needle-free influenza vaccine that has long been approved by the United States Food and Drug Administration and has recently received approval for use in Singapore. Delivered as a nasal spray rather than an injection, it offers an alternative for individuals who wish to protect themselves against seasonal flu but are hesitant about needles. In Singapore, it is currently approved for administration in clinical settings only. “The flu is more than just a bad cold — it can knock you down for weeks. Getting vaccinated is the simplest way to protect yourself and your loved ones. With needle-free options like FluMist, staying protected has never been easier.” - Dr Sankeerth Reddy Expanding Beyond Aesthetics into Preventive Care Zest Clinic’s core services include aesthetic medicine, men’s and women’s health, and wellness and longevity programmes such as health screenings and selected vaccinations. The introduction of an intranasal flu vaccine extends this preventive care work, allowing patients who visit for aesthetic or wellness reasons to address broader health concerns in the same setting under medical supervision. How the Intranasal Flu Vaccine Works FluMist is delivered as a fine mist into the nostrils. Instead of an intramuscular injection, a small volume of spray exposes the nasal passages to weakened influenza viruses that help the body build immunity against circulating strains. By targeting the entry point of many respiratory infections, the vaccine stimulates both local and systemic immune responses. The local (nasal mucosa) protection is what makes it a game changer compared to the injectable form. Clinical Effectiveness and Patient Selection International data indicate that intranasal influenza vaccines can be at least as effective as traditional injectable vaccines in specific age groups and seasons, but they are not suitable for everyone. Individuals with certain chronic medical conditions, weakened immune systems or other contraindications may be better served by an inactivated injectable vaccine, in line with current recommendations. It has been approved for individuals between the age 2 years to 49 years. At Zest Clinic, every vaccination is preceded by a medical consultation to review the patient’s history and risk profile. The choice between FluMist and an injectable influenza vaccine is based on clinical considerations and patient preferences. “Influenza Immunisation is not just about protecting one person — it’s about protecting the whole family. When parents, children, and grandparents are vaccinated, we create a strong shield that helps prevent infections from spreading at home and in the community. A family that vaccinates together stay strong together.” - Dr Tiffany Yeo- Reddy Clinic-Administered Only in Singapore Unlike in some overseas settings where intranasal influenza vaccines may be used at home, FluMist in Singapore is currently approved for clinic use only. At Zest Clinic, the vaccine is administered by trained staff in a controlled environment, with brief post-vaccination observation so that any immediate side effects, such as mild nasal irritation, can be monitored. The vaccination is $60 Nett Price. About Zest Clinic Zest Clinic is located at Parkway Parade Medical Centre, 80 Marine Parade Road, Singapore. The clinic provides aesthetic medicine, men’s and women’s health services, and wellness and longevity programmes, including health screenings and vaccinations. Its team of doctors and staff aim to combine evidence-based medical care with a patient-centred approach that considers both appearance and long-term health. Media and RSVP Contact Zest Clinic 80 Marine Parade Road, #05-04/05 Parkway Parade Medical Centre Singapore 449269 Tel / WhatsApp: +65 9176 9378 Email: info@zest.clinic https://www.zest.clinic/ Dr. Tiffany Yeo-Reddy Zest Clinic +65 6995 0470 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug ApprovalVaccine

10 Oct 2025

·www.pharmaceutical-technology.com

Flu vaccine uptake increases 28% in England

There are currently seven licensed flu vaccines available for the 2025 to 2026 season. Tong_stocker via Shutterstock.com. The number of people receiving a flu vaccine across England has increased by over a quarter, as cases of both influenza and Covid-19 start to climb at the start of the viral season. Data from England’s National Health Service (NHS) shows that the flu jab has been administered to 4.3 million people, a 28% rise from 3.36 million who received the vaccine at the same point last year. The vaccination drive comes as the flu season commences. Influenza infections start to uptick around October, with peaks usually coming in December. Vaccines can help protect against the flu and are offered to people every year at higher risk of becoming seriously ill. Caused by the influenza virus, flu is significantly more serious than the common cold, which is caused by a wide range of viruses. The UK Health Security Agency’s (UKHSA’s) latest surveillance data showed that flu positivity increased from 1.9% to 3.3% and Covid-19 positivity in hospital settings increased from 11.7% in the previous week to 12.9%. One of the key changes to this year’s vaccine programme is the switch from quadrivalent (QIV) to trivalent (TIV) vaccines in inactivated influenza vaccines (IIV). The World Health Organization (WHO) recommends the composition of influenza vaccine strains each year based on global virus trends. For the 2025/26 season, WHO recommends the use of the trivalent vaccine for the Northern Hemisphere. This is because the influenza B/Yamagata lineage virus has not been detected worldwide since 2020 and is not predicted to cause future epidemics. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence There are currently seven licensed flu vaccines available for the 2025 to 2026 season. CSL Seqirus’ cell-based quadrivalent influenza vaccine, Sanofi’s Vaxigrip, and Viatris’ Influenza vaccine TIV MYL are given to those above six months of age. AstraZeneca’s Fluenz Tetra, a live attenuated influenza vaccine (LAIV), is for those between two and 18 years of age. For adults over 18 years of age, Sanofi’s Supemtek, a recombinant trivalent influenza vaccine, is used. CSL Seqirus’ other adjuvanted trivalent influenza vaccine is licensed for use for adults above 50 years of age. Sanofi’s Efluelda TIV-HD is available to those 60 years of age and over. The NHS offers flu vaccines for everyone aged 65 and over, and for adults 18 to 64 years of age in certain risk groups. The NHS is bracing itself for a busy winter. Regional teams are improving access to the vaccines through mobile vaccination buses, family community drop-in sessions, and, in an NHS first, delivering flu vaccines to two and three-year-olds in community pharmacies. Meanwhile, eligibility for the Covid-19 vaccine changed for this autumn and winter following an update on recommendations by the Joint Committee on Vaccination and Immunisation (JCVI). The committee advises that the vaccines be offered to people aged 75 or over, residents in care homes, or anyone with a weakened immune system. Dr Amanda Doyle, national director for Primary Care and Community Services at NHS England, said : “Vaccination is a crucial part of our efforts to protect the vulnerable and prepare for what we expect to be a very challenging winter, so I’m delighted to see this big increase in the numbers of people getting vaccinated at this stage. “Vaccinations are our best defence against these potentially very dangerous viruses and can genuinely save lives.” Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

VaccineDrug Approval

19 Aug 2025

·www.drugs.com

Nasal Spray Flu Vaccine, FluMist, Now Available for At-Home Use

TUESDAY, Aug. 19, 2025 — For the first time, people can get their annual flu vaccine without leaving the comfort of home. FluMist , a nasal spray flu vaccine made by AstraZeneca, is now available for at-home use through a service called FluMist Home, the company announced. The U.S. Food and Drug Administration (FDA) first approved FluMist in 2003 for use in doctors’ offices and pharmacies. Last year, the FDA expanded approval, making it the first flu vaccine that can be self-administered, CBS News said. FluMist Home allows customers to order the same nasal spray available at clinics, shipped directly to their homes. It will be offered in 34 states during the 2025-2026 flu season. The cost of FluMist is covered by most commercial insurance, though there is an $8.99 shipping and processing fee, according to the online ordering platform. To order, customers provide personal information, medical history, insurance details and a payment. FluMist is approved for people ages 2 to 49. Caregivers should administer the vaccine to children ages 2 to 17, according to the FDA. The vaccine should not be used in people with severe allergies to its ingredients, eggs or other flu vaccines, according to the company . Full safety information and administration instructions are provided on the product website. FluMist Home will launch in these states for the 2025-26 flu season: Alabama Alabama Arizona Arizona California California Colorado Colorado Connecticut Connecticut Florida Florida Georgia Georgia Iowa Iowa Idaho Idaho Illinois Illinois Massachusetts Massachusetts Maryland Maryland Maine Maine Michigan Michigan Montana Montana North Carolina North Carolina North Dakota North Dakota Nebraska Nebraska New Hampshire New Hampshire New Jersey New Jersey Nevada Nevada Ohio Ohio Oregon Oregon Pennsylvania Pennsylvania South Carolina South Carolina South Dakota South Dakota Tennessee Tennessee Texas Texas Utah Utah Virginia Virginia Vermont Vermont Washington Washington Wisconsin Wisconsin Wyoming Wyoming The company noted that local pharmacy laws prevent it from being available everywhere. Sources CBS News, Aug. 15, 2025

Drug ApprovalVaccine

100 Deals associated with Influenza virus vaccine live intranasal (quadrivalent)(MedImmune LLC)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07BB03	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Influenza, Human	European Union	AstraZeneca AB	04 Dec 2013
Influenza, Human	Iceland	AstraZeneca AB	04 Dec 2013
Influenza, Human	Liechtenstein	AstraZeneca AB	04 Dec 2013
Influenza, Human	Norway	AstraZeneca AB	04 Dec 2013
Influenza A virus infection	United States	MedImmune LLC	17 Jun 2003
Influenza B virus infection	United States	MedImmune LLC	17 Jun 2003

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Influenza-like symptoms	Phase 3	Japan	AstraZeneca PLC	01 Oct 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06501963 (PRISM, CTgov)	Phase 4	Influenza, Human	51	Live Attenuated Influenza Vaccine	cgnvrnmjya(nwyhzgcljx) = faeldevsxy legefvyofu (zdausapjhm, 1.79) View more	-	30 Mar 2026
NCT03982069 (CTgov)	Phase 4	Influenza, Human	465	FluMist live attenuated influenza vaccine (FluMist Live Attenuated Influenza Vaccine)	bxkffnaeod(fmxvplpaiv) = gqkwqolasz wyzkvwxmvj (bslousjukn, yqkbebjwal - jjhyowrnhu) View more	-	14 Oct 2021
				Flucelvax inactivated influenza vaccine (Flucelvax Inactivated Influenza Vaccine)	bxkffnaeod(fmxvplpaiv) = aayyehjfgi wyzkvwxmvj (bslousjukn, zvftiucsay - ixipcbsfid) View more
NCT03101462 (CTgov)	Phase 4	Influenza, Human	38	IIV (Inactivated Influenza Vaccine (IIV))	slbnvsspzk(pgwvqhzfje) = jzmpawdodp xljkjxspyq (bbhbgguhga, wfeakhnezx - zmddhfudlk) View more	-	06 Mar 2019
				LAIV (Live Attenuated Influenza Vaccine (LAIV))	slbnvsspzk(pgwvqhzfje) = muhplgyqpm xljkjxspyq (bbhbgguhga, brqjlsilpv - tgcyhyatxu) View more
NCT03028974 (CTgov)	Phase 4	Influenza, Human	77	FluMist® (Group A: 2-4 yo LAIV4 (Return))	bjzwikikac = svmwropyui dfissalrqw (olosbfvktt, miolguotmu - cqlpexnubc) View more	-	14 Dec 2018
				Fluzone® (Group E: 6 - 23 Mos Old IIV4 (Single Yr))	tcuoitipci = gmtuszqybf bsyzrgrfqp (iogmwkcvlr, lmdttmnbul - ovsecjomiu) View more
NCT03143101 (FluMist, CTgov)	Phase 4	Influenza, Human	200	FluMist trivalent (FluMist Trivalent (2015-2016))	chbwyapigo = mzhktmxjss kqhyonxumi (mprbigupmu, tgzaforrrj - cdagujnhsv) View more	-	11 Dec 2018
				FluMist Quadrivalent (FluMist Quadrivalent (2015-2016))	chbwyapigo = ojjyqngwqp kqhyonxumi (mprbigupmu, whpypbyaks - ooylsittot) View more
NCT02474901 (QLAIV, CTgov)	Phase 2	Influenza, Human	101	Quadrivalent Live Attenuated Influenza Vaccine (QLAIV, HIV-infected)	cwcwmfebqc = fdfanibqly bpotfpdzjl (arkuesbahc, wxzgypclnd - lsykutwyft) View more	-	16 Oct 2017
				Quadrivalent Live Attenuated Influenza Vaccine (QLAIV, HIV-uninfected)	cwcwmfebqc = uwgtpngomv bpotfpdzjl (arkuesbahc, dorjbamdrv - ahqjprlhme) View more
NCT01933048 (SNIF, CTgov)	Phase 4	Influenza, Human	1,077	FluMist (Healthcare Worker Administration)	zvfduxswru(ldyqrjjjwz) = uptlrkuldt sutkjptgfv (sgezlaoenq, sljpczbvdz - wghkiouslf) View more	-	12 Sep 2017
				FluMist (Self-Administration)	zvfduxswru(ldyqrjjjwz) = hqqrooawxs sutkjptgfv (sgezlaoenq, vnevpepwbe - rwnzexwmoq) View more
NCT03028987 (CTgov)	Phase 4	Influenza, Human	10	FluMist® (LAIV Randomized)	vsiochhbeb = zdfqouxleu myflsmmgtn (fhinhaclan, yzpnegmcpi - trtijuwxzf) View more	-	12 Sep 2017
				Fluzone® (IIV4 Randomized)	vsiochhbeb = qyxkxmmdpn myflsmmgtn (fhinhaclan, qfsctvdpeo - pqlskubapa) View more
NCT02141581 (CTgov)	Phase 4	Influenza, Human	86	Fluzone® (IM)	jwjfbjtpuj = yvthiyespk jyvcebpfvw (qcinjermbl, ktbbamuetl - zgmudjbpfz) View more	-	11 May 2017
NCT03023709 (CTgov)	Phase 4	Influenza, Human	3	Fluzone® (Pilot Phase)	eyeevwtpcd = dtavflmvkm qcdpwdzrss (vgmbhevhfq, nmeinvwxqg - owxegwftpx)	-	10 May 2017
				FluMist® (Study Phase)	eyeevwtpcd = fzjsicdryj qcdpwdzrss (vgmbhevhfq, pzkpisusna - fseprulgsg)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis